Article and Video CATEGORIES

Cancer Journey

Search By

 

Dr. Aakash Desai, MBBS, MPH serves as an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. His pioneering research is primarily concentrated in the realm of evidence-based oncology, clinical trials, drug development, healthcare delivery, and quality of cancer care. He holds a particular interest in Thoracic Oncology and drug development.

Click here for more information about Dr. Desai. 

 

Program: LCVL 2023
Oncologists discuss a variety of topics in lung cancer, including biomarker testing, immunotherapy, KRAS+ disease, and emerging therapies, among other topics.

Author
Aakash Desai, MD, MPH - Guest Faculty
Image
LCVL 2023

In this latest update to the Lung Cancer Video Library, Oncologists discuss a variety of topics in lung cancer including biomarker testing, immunotherapy, KRAS+, emerging therapies, the changes that have occurred in treating NSCLC in the past few decades, Lung Cancer risk factors, and treatment options.

To watch the full playlist click here.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.